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Abstract
Background and Aims: Cost-effective screening strategies are needed to make hepa-
titis C virus (HCV) elimination a reality. We determined if birth cohort screening is 
cost-effective in Italy.
Methods: A model was developed to quantify screening and healthcare costs associ-
ated with HCV. The model-estimated prevalence of undiagnosed HCV was used to 
calculate the antibody screens needed annually, with a €25 000 cost-effectiveness 
threshold. Outcomes were assessed under the status quo and a scenario that met the 
World Health Organization's targets for elimination of HCV. The elimination scenario 
was assessed under five screening strategies.
Results: A graduated birth cohort screening strategy (graduated screening 1: 1968-
1987 birth cohorts, then expanding to 1948-1967 cohorts) was the least costly. This 
strategy would gain approximately 144 000 quality-adjusted life years (QALYs) by 
2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 
89.7% and 88.7% reduction for inversed graduated screening, 1948-77 birth cohort, 
1958-77 birth cohort and universal screening, respectively. Graduated screening 1 
yielded the lowest incremental cost-effectiveness ratio (ICER) of €3552 per QALY 
gained.
Conclusions: In Italy, a graduated screening scenario is the most cost-effective strat-
egy. Other countries could consider a similar birth cohort approach when developing 
HCV screening strategies.
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1  | INTRODUC TION
Hepatitis C virus (HCV) is a leading cause of liver-related morbidity 
and mortality, causing an estimated 71 million infections globally.1 
The size of the infected population and the risk of severe compli-
cations make HCV a serious public health problem.2 However, the 
use of direct-acting antiviral (DAA) therapy regardless of fibrosis 
stage is the current standard of care in many high-income countries. 
Thus, the limitation of HCV therapy is no longer treatment efficacy 
or adherence, but the identification of available patients to treat. 
Achieving the World Health Organization (WHO)'s Global Health 
Sector Strategy (GHSS) goals for the elimination of HCV by 20303 
has reinvigorated public health initiatives aimed at identifying pa-
tients with the disease. Studies originally suggested finding and di-
agnosing populations at risk for the acquisition and transmission of 
HCV. While targeted screening program for high-risk populations, 
such as injection drug users, are necessary for the elimination of 
HCV,4,5 more is needed to identify what increases in diagnosis are 
necessary in the general population of high-endemic countries for 
achieving elimination.
Italy has been considered the European country with one of 
the largest burdens of HCV in the general population, with the 
highest prevalence in the older population and decreasing risk 
in younger populations.6,7 The HCV prevalence in the country is 
approximately 1%, though previous studies have estimated rates 
as high as 7% in those born between 1935 and 1944, while those 
aged 30 years and younger are at less risk of acquiring HCV.7 A 
large number of infections occurred from the 1950s to the 1960s 
via iatrogenic transmission due to the use of unsterilized materi-
als.6,7 More so, there are geographical differences in prevalence 
distribution. The highest rates of HCV have been reported in 
Southern Italy, where the HCV prevalence in younger cohorts is 
quite limited.6–8 Considering the natural history of chronic HCV 
infection and the wide use of antiviral therapy in Italy, total HCV 
cases still remain higher than in other European countries, such 
as Spain and France.9 With more than 56 000 patients treated 
in 2018, Italy has taken substantial strides in managing its HCV 
disease burden. However, the number of HCV-infected individ-
uals available to treat is estimated to run out by 2025 given the 
current treatment rates, leaving a large proportion of individuals 
with the potential to progress to later stage liver disease.8 Thus, 
cost-effective screening strategies are needed to make elimi-
nation a reality in Italy. We aimed to determine the cost-effec-
tiveness of expanded HCV screening strategies among different 
population cohorts in Italy.
2  | MATERIAL S AND METHODS
2.1 | Study design
An Excel-based Markov disease burden model1 was populated with 
Italian data to quantify the annual HCV-infected population by liver 
disease stage, sex and age.8 The model simulates the natural his-
tory of the disease and forecasts disease burden, medical costs and 
health effects of HCV, assessed under the status quo and a scenario 
to achieve the WHO's GHSS targets (80% reduction in incidence of 
chronic HCV infections between 2015 and 2030, 65% reduction in 
HCV-related deaths due to chronic HCV infection between 2015 
and 2030, 90% diagnosis coverage of the HCV-infected population 
in 2015 and 80% treatment coverage of the eligible HCV-infected 
population in 2015)3 considering five screening strategies:
1. Status quo: only at-risk populations screened in Italy,2
2. Targeted general population screening for the 1948-77 birth 
cohort,81
3. Targeted general population screening for the 1958-77 birth 
cohort,8 
 1These two screening strategies are based on a previous modelling study,8 which 
estimated more than 70% of infected (F0-F3) individuals were within the 1948-1978 
birth cohorts by 2020.
interpretation of the data, in the writing of 
the report and in the decision to submit the 
paper for publication.
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Key points
In 2016, the World Health Assembly passed a resolution to 
eliminate hepatitis infection by 2030 and the World Health 
Organization (WHO) introduced global targets for the care 
and management of HCV infection, known as the Global 
Health Sector Strategy (GHSS) goals for hepatitis. The lack 
of available patients linked to care and available to treat, 
however, remains the key bottleneck for several countries 
aiming to achieve HCV elimination. The data reported in 
this study are of importance in that they demonstrate the 
cost-effective profiles of several HCV screening strate-
gies in the general population of a high-endemic country. 
Differentiated screening strategies based on epidemiologi-
cal peculiarities of HCV infection can support increases in 
diagnosis and subsequent treatment of infected patients 
necessary for realizing elimination.
See Editorial on Page 1538 
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4. Graduated birth cohort screening 1 (birth cohorts 1968-1987 be-
ginning in 2020 to identify young populations at risk for transmit-
ting HCV, expanding to the 1948-1967 birth cohort beginning in 
2023 to identify older populations before their disease advances),
5. Graduated birth cohort screening 2 (birth cohorts 1948-1967 be-
ginning in 2020 to identify older populations before their disease 
advances, and the younger birth cohort 1968-1987 at risk for 
transmitting HCV beginning in 2023),
6. Universal screening: The entire Italian population was considered 
to be screened.
2.2 | Input parameters
The Italian HCV-infected population, with or without a prior HCV 
diagnosis,7 disease burden,8 cost (in euros)10,11 and health-related 
quality of life measures12 was obtained from the recently published 
literature (Table 1). The number of patients treated with DAAs from 
2015 to 2018 was available through the Agenzia Italiana del Farmaco 
(AIFA, The Italian Medicines Agency).13 The per-patient cost asso-
ciated with implementing each screening strategy was calculated, 
considering the proportion of persons who inject drugs (PWID) in 
each cohort. Higher implementation costs were assumed for iden-
tifying cases among PWID (€55 per person screened) relative to 
the general population (€15 per person screened). The estimated 
proportion of PWID in each cohort is calculated and summarized 
in Appendix S2. Briefly, a standardized mortality ratio was applied 
to the 15- to 44-year-old HCV-infected population, considering the 
proportion of the HCV-infected population that is actively inject-
ing. Using this estimated proportion, the average screening cost per 
person, per scenario, was calculated (Appendix S2). Prevalence of 
asymptomatic HCV infections not yet linked to care was used to 
calculate the number of HCV antibody screens needed annually to 
diagnose one case, as described in Appendix S1.
2.3 | Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were conducted 
for each scenario to identify the drivers in the model that accounted 
for the greatest variation in the incremental cost-effectiveness 
ratio (ICER) and to generate 95% uncertainty intervals (UIs) around 
the ICER, given uncertainties in model parameters, using Crystal 
Ball, a Microsoft Excel (Microsoft Corporation) add-in by Oracle 
(Oracle Corporation). In accordance with the International Society of 
Pharmacoeconomics and Outcomes Research,14 costs were assumed 
to be gamma-distributed and quality-adjusted life year (QALY) utilities 
were assumed to be beta-distributed (Table 1). Uncertainty in starting 
prevalence was not considered, since the ICER was calculated rela-
tive to the status quo, and the starting prevalence under the status 
quo would be the same as the prevalence under a screening scenario. 
Finally, to determine the impact of uncertainty in the cost of screen-
ing on the variation in ICER, deterministic and probabilistic sensitivity 
analyses were conducted for the scenario found to be the most cost-
effective, assuming a beta-PERT-distributed cost of screening among 
both low- and high-risk groups, with a minimum of half the base-case 
price and a maximum of double the base-case price (Table 1).
2.4 | Role of the funding source
This study was supported by the Italian Ministry of Health, grant 
number RF-2016-02364053 and by a Research Grant from the 
University of Tor Vergata Rome. The funding source had no role in 
the study design, the collection, analysis and interpretation of the 
data, in the writing of the report and in the decision to submit the 
paper for publication.
3  | RESULTS
Under the status quo, 290 400 persons would be diagnosed 
and linked to care, corresponding to 11.3 million screening tests 
(Figure 1; Table 2). Additionally, 309 200 patients would be initiated 
on treatment between 2018 and 2031. Total viraemic infections and 
liver-related deaths (LRDs) would decline 65% by 2031 (Figure 1). 
Although this meets the WHO target for a reduction in LRDs, Italy 
would not achieve the incidence and diagnosis targets.
A WHO target scenario (Table 2) was assessed under five dif-
ferent screening strategies. Under these scenarios, between 15.0 
million and 55.4 million screening tests would be performed to di-
agnose between 340 400 and 385 300 persons (Figure 1). Under 
all screening scenarios, 548 500 persons would start treatment be-
tween 2018 and 2031, resulting in an accelerated drop in the num-
ber of viraemic cases and LRDs (11 100-15 300 LRDs averted) by 
2031, relative to the status quo. The screening scenarios result in an 
89.3%, 89.6%, 89.0%, 89.7% and 88.7% reduction in HCV cases for 
graduated screening 1, graduated screening 2, 1948-77 birth cohort, 
1958-77 birth cohort and universal screening, respectively.
The results of the cost-effectiveness analysis are presented in 
Table 3 and shown in Figure 2. Under the status quo, annual screen-
ing costs would increase 55%, from €3.4 million in 2018 to €5.3 
million by 2031. Annual direct medical costs would show a 70% 
reduction, from €783.5 million in 2018 to €214.1 million by 2031, 
cumulating to €5.5 billion over the study period.
Compared to the status quo, all screening scenarios were found to 
be highly cost-effective, with an ICER of €3552/QALY (95% UI 1486-
6114) for graduated screening 1, €4349/QALY (95% UI 2265-7014) 
for screening the 1948-77 birth cohort, €4532/QALY (95% UI 2102-
7610) for graduated screening 2, €4831/QALY (95% UI 2470-7973) for 
screening the 1958-1977 birth cohort and €6758/QALY (95% UI 4589-
9481) for universal screening. The graduated screening 1 scenario 
was the least costly, with €6.0 billion in total direct medical costs by 
2031. This was €54.3 million less than graduated screening 2, €107.4 
million less than screening in the 1948-77 birth cohort, €109.1 million 
less than screening in the 1958-1977 birth cohort and €467.1 million 
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TA B L E  1   Direct medical cost and health effect input parameters
 Parameter Base Distribution
First parameter 














Total screening cost, 
low-risk groupsa 
15.00 Beta-PERT 7.50 30.00 Sum of price of HCV antibody testb  
and per-screen implementation 
costc , assuming half the total cost as 
minimum and double the total cost as 
maximum
Total screening cost, 
high-risk groupsa 
55.00 Beta-PERT 27.50 110.00 Sum of price of HCV antibody testb  
and per-screen implementation 
costc , assuming half the total cost as 
minimum and double the total cost as 
maximum
RNA test/PCR 63.01 — — — Ministero della Salute 2013 (code 
91.19.3)
Genotyping 77.47 — — — Ministero della Salute 2013 (code 
91.20.2)
Fibroscan 50.00 — — — 10,11
Lab costs 50.00 — — — 10,11
Antiviral treatment 4000.00 — — — 10,11
Healthcare 
costs (€)
Fibrotic (F0-F3) — Gamma 100.00 2.77 10,11
Comp. cirrhosis — Gamma 100.00 8.76 10,11
DCC — Gamma 100.00 66.26 10,11
HCC — Gamma 100.00 128.96 10,11
LTx, first year — Gamma 100.00 737.74 10,11
LTx, subs years — Gamma 100.00 23.65 10








Fibrotic (F0-F3) — Beta 11.12 1.52 12
Comp. cirrhosis — Beta 16.17 3.31 12
DCC — Beta 26.27 9.72 12
HCC — Beta 46.47 41.21 12
LTx, first year — Beta 26.27 9.72 12
LTx, subs years — Beta 26.27 9.72 12




Fibrotic (F0-F3) 1 — — — 12
Comp. cirrhosis Same as pre-SVR
DCC Same as pre-SVR
HCC Same as pre-SVR
LTx, first year Same as pre-SVR
LTx, subs years Same as pre-SVR
Abbreviations: comp. cirrhosis, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; 
LTx, subs years, liver transplant, subsequent years; LTx, liver transplant; PCR, polymerase chain reaction; QALY, quality-adjusted life year; RNA, 
ribonucleic acid; SVR, sustained virologic response.
aUncertainty in input considered in the most cost-effective scenario. 
bAssumption and [18]. 
cAssumption. 
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less than universal screening. Relative to the status quo, graduated 
screening 1 would gain approximately 144 000 QALYs by 2031, com-
pared to 125 000, 145 000, 142 000 and 128 000 QALYs for grad-
uated screening 2, universal, 1948-1977 birth cohort and 1958-77 
birth cohort screening, respectively. Excluding the three scenarios that 
were costlier and less effective than graduated screening 1, universal 
screening yielded an ICER of €562 855 per QALY relative to graduated 
screening 1.
One-way sensitivity analysis showed that more than 90% of the 
variation in the 2018-2031 ICER was due to the annual follow-up 
F I G U R E  1   Cumulative diagnosed patients and screens, as well as modelled viraemic cases and liver-related deaths, by scenario, 2018-
2031. GHSS, Global Health Sector Strategy; HCV, hepatitis C virus
TA B L E  2   Scenario inputs, 2017-2031
Status quo 2017 2018 2019 2020 2021 2022 2025+
Treated 45 000 56 400 44 600 33 700 23 200 15 100 15 100
Newly diagnosed/newly linked 
to care
30 400 30 400 20 ,000 20 000 20 000 20 000 20 000
Fibrosis score restriction ≥F0 ≥F0 ≥F0 ≥F0 ≥F0 ≥F0 ≥F0
New infections 8200 7500 6700 6100 5600 5200 5200
Treated ages 15+ 15+ 15+ 15+ 15+ 15+ 15+
SVR 95% 95% 98% 98% 98% 98% 98%
GHSS elimination 2017 2018 2019 2020 2021 2022 2025+
Treated 45 000 56 400 44 600 35 700 35 700 36 700 38 000
Incremental newly diagnosed/
newly linked to care
— — 10 400 13 400 13 400 15 400 16 400
Fibrosis score restriction ≥F0 ≥F0 ≥F0 ≥F0 ≥F0 ≥F0 ≥F0
New infections 8200 7500 6700 5500 5000 4100 2600
Treated ages 15+ 15+ 15+ 15+ 15+ 15+ 15+
SVR 95% 95% 98% 98% 98% 98% 98%
Abbreviations: GHSS, Global Health Sector Strategy; SVR, sustained virologic response.
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costs of cirrhosis, decompensated cirrhosis, hepatocellular car-
cinoma, the QALY utility for cirrhosis and the cost of liver trans-
plantation (Figure 3). Since the choice of scenario does not make a 
difference in the ranking of uncertain parameters by explained vari-
ation in the ICER, only results for the graduated screening scenario 
1 were reported. The probabilistic sensitivity analysis revealed that, 
at a willingness to pay (WTP) threshold of €25 000 per QALY gained, 
all scenarios were cost-effective 100% of the time (Figure 4).
Allowing for uncertainty (ie varying the price from half to up to 
double the assumed base price of screening) in the cost of screening 
among both low- and high-risk groups, graduated screening 1, which 
was the most cost-effective scenario relative to the status quo, had 
an ICER of €3552/QALY (95% UI 1570-6359). One-way sensitivity 
analysis revealed that more than 90% of variation in the ICER was 
mainly due to the annual follow-up costs of cirrhosis, decompensated 
cirrhosis, hepatocellular carcinoma, followed by the cost of screening 
among low-risk groups, the QALY utility for cirrhosis and the cost of 
liver transplantation (Figure 5A). The probabilistic sensitivity analysis 
showed that at a WTP of €25 000, graduated screening 1 remained 
cost-effective 100% of the time (Figure 5B).
TA B L E  3   Direct medical costs and health effects, by scenario, 2018-2031
Scenario




ICER relative to status 
quo (€/QALY)
ICER relative to previous 
least costly scenario  
(€/QALY)
Status quo 5463 – –  
GHSS 
Targets
Graduated screening 1 5974 144 000 3552 3552
Graduated screening 2 6028 125 000 4532 a 
Screening 1948-1977 6081 142 000 4349 a 
Screening 1958-1977 6083 128 000 4831 a 
Universal screening 6441 145 000 6758 562 855
Note: Values have been rounded, so ICERs may not be reproducible using table values.
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; GHSS: Global Health Sector Strategy.
aStrongly dominated scenario (costlier and less effective than another scenario). 
F I G U R E  2   Economic impact of scenarios as measured by screening costs, direct medical costs, QALYs gained relative to the status quo 
and 13-year ICER, by scenario, 2018-2031. EUR, euros; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life year
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4  | DISCUSSION
This study aimed to evaluate the cost-effectiveness of five poten-
tial HCV screening strategies in Italy. The universal screening and 
birth cohort screening scenarios, which achieve all targets of the 
HCV elimination goals, were found to be cost-effective when com-
pared to the status quo scenario, suggesting a coordinated screen-
ing program may be beneficial in moving Italy towards elimination 
of HCV.
4.1 | Birth cohort screening
We evaluated the cost-effectiveness of screening in the birth cohorts 
1948-1988, as they were previously identified as having the highest 
prevalence of undiagnosed HCV infection.8 Screening the 1948-77 
birth cohort would result in fewer QALYs gained compared to the 
universal and graduated screening 1 scenario and cost less than the 
universal screening scenario, but more than the graduated screening 
strategies. Other studies also found that targeted screening among 
F I G U R E  3   One-way sensitivity analysis for the 2018-2031 incremental cost-effectiveness ratio, graduated screening 1 scenario. The 
central vertical line in the tornado diagram represents all parameters at base values and the base 2018-2031 cost-effectiveness ratio for the 
graduated screening 1 scenario. The horizontal bars represent the variation in the incremental cost-effectiveness ratio given the variations 
in the parameters of the scenario. The variables are arranged by explained variation in the incremental cost-effectiveness ratio, with ‘Annual 
follow-up cost, Cirrhosis’ being the most impactful. DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; QALY, quality-adjusted 
life year
F I G U R E  4   Cost-effectiveness 
acceptability curve, by scenario. The cost-
effectiveness acceptability curve shows 
the proportion of Monte Carlo simulations 
resulting from varying cost and QALY 
(quality-adjusted life year) parameters 
that are cost-effective given a willingness 
to pay threshold. QALY, quality-adjusted 
life year
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sub-populations with high HCV prevalence is cost-effective.15,16 In 
a previous meta-analysis of all available cost-effectiveness stud-
ies before the availability of DAAs, the cost per QALY gained of 
screening programs among asymptomatic cohorts at general risk for 
HCV ranged between US $4200 and $50 000. This was much lower 
than focusing on specific risk groups, which had an estimated ICER 
F I G U R E  5   A, One-way sensitivity analysis for the 2018-2031 incremental cost-effectiveness ratio, including uncertainty in cost of 
screening, graduated screening 1 scenario. B, Cost-effectiveness acceptability curve, including uncertainty in cost of screening, graduated 
screening 1 scenario. DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; QALY, quality-adjusted life year
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of between $848 and $128 424 per QALY gained. In the study, age 
of the target population to be screened and prevalence were the 
main drivers of cost-effectiveness.17 These are also important driv-
ers for developing screening strategies in Italy.18 Despite the lower 
rates of drug use across Italy compared to other countries, this risk 
group represents the most recent wave of new infections,19 which in 
addition to other high risk populations as imnates and migrants are 
mainly distributed among the 1968-1988 birth cohorts,20–22 who are 
asymptomatic. Without including these groups in specific screening 
policies, continued disease burden is expected. Additionally, results 
of the sensitivity analysis, which examined the cost-effectiveness 
of each strategy using a €25 000/QALY WTP threshold, remained 
high (P > 99%) once the uncertainty in parameters was considered. 
Parameters relating to the disease state costs and health outcome 
utilities were found to have the highest impact on the cost-effec-
tiveness results.
4.2 | Graduated screening
Consequently, the graduated screening strategies aim to capture indi-
viduals who may be at a higher risk for HCV but are currently asymp-
tomatic. The graduated screening 1 scenario, which identifies young 
populations at risk for transmitting HCV before expanding to identify 
older populations before their disease advances, was the least costly 
screening strategy, with €6.0 billion in direct medical costs by 2031. 
Relative to the status quo, graduated screening 1 would gain ap-
proximately 144 000 QALYs by 2031, which was more than the other 
birth cohort strategies and also produced a lower ICER. The gradu-
ated screening 2 scenario, which first identifies older populations be-
fore their disease advances and then screens younger cohorts at risk 
for transmitting HCV, was also less costly (€6.0 billion), but had fewer 
QALYs gained (125 000) compared to graduated screening 1 scenario. 
From a disease burden perspective, both graduated screening strategies 
have significant impact on overall reduction in total viraemic infections 
and liver-related mortality by 2031 (Figure 1), though graduated screen-
ing scenario 1 results in more QALYs gained because it is more likely to 
identify asymptomatic individuals early and prevent the progression of 
liver disease. Additionally, both graduated scenarios were found to be 
highly cost-effective (as seen in Table 3). Even upon allowing for a wide 
variation in the cost of screening among both low- and high-risk groups, 
the graduated screening 1 scenario remained highly likely (P > 99%) 
to be cost-effective at the €25 000/QALY WTP threshold (Figure 5B). 
Screening in this younger cohort would likely detect individuals at higher 
risk of infectiousness, decreasing the potential to transmit new infec-
tions compared to screening older patients who are more likely already 
identified and less likely to contribute to further disease burden.
4.3 | Programmatic considerations
It is important for policymakers to consider not only the cost-ef-
fectiveness of such strategies, but also their implementation and 
sustainability. Though the universal screening strategy is recently 
recommended,23,24 it requires higher initial up-front investment, 
while the graduated strategy 1 would result in a similar number of 
QALYs gained and have the largest decline in LRDs and associated 
mortality, limiting the initial cost of the investment. Other high-in-
come countries have reported the opposite, where the epidemiol-
ogy of chronic HCV infection differs from the situation in Italy.6,7,23 
In the United States, for example, a larger proportion of new HCV 
transmission is driven by injection drug use among younger popula-
tions, meaning universal screening would capture these individuals 
who are likely asymptomatic.25 In Italy, risk-based HCV testing should 
be implemented independently by birth cohort. Those aged 30 years 
and younger without high-risk behaviours, however, are at less risk 
of acquiring HCV infection.7 Therefore, a graduated screening strat-
egy in the general population, which captures both groups, is recom-
mended, as it is immediately cost-effective without high initial costs 
like the universal screening strategy.
4.4 | Limitations
This study has several limitations that could affect the robustness 
of the model and the impact of the results. This model does not 
dynamically estimate new infections and reinfections, nor does it 
focus on treatment as prevention. However, the current treatment 
rate in Italy and the need to expand such treatment levels in order 
to achieve the GHSS targets exceed the proportion required for 
treatment when compared to other transmission-based models.26 
Next, the cost-effectiveness of a screening strategy is strongly 
linked to the patient's disease stage at the time of treatment ini-
tiation. If treatment is delayed and only patients with severe fibro-
sis are screened, those with more severe liver disease will accrue 
higher costs, reducing the impact on QALYs. Additionally, the true 
cost of DAA treatment in Italy is unknown. A previous analysis es-
timated that at €4000, treating all patients compared to treating 
symptomatic individuals would be both cost-effective and cost-
saving.12 Subsequently, this was assumed a reasonable estimate 
for the cost of therapy. As discussed in a recent systematic review, 
analyses should consider this rapidly varying cost of DAAs;27 how-
ever, drug price was not found to be an important factor in the sen-
sitivity analysis. Further, this study partially considered the related 
costs of healthcare management and reliability of screening tests. 
In particular, the adequate organizational, health system-level and 
operational costs regarding screening of HCV are only partially 
considered in this study. While diagnosed and immediate initiation 
of DAA therapy would be the most efficient strategy, screening 
strategies which further consider the cost for general practition-
ers to screen and diagnosis HCV patients, though included empiri-
cally here, have not yet been fully evaluated. Thus, this modelling 
work requires real-life validation in different Italian regions. One 
such validation study has been carried out in another high-income, 
European country. Recent findings from a population-based, cross-
sectional study in Spain found that a stepwise screening strategy, 
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similar to the graduated screening 1 scenario described here, was 
cost saving,28 supporting that this type of strategy may be feasible. 
Though graduated or birth cohort screening is less costly than uni-
versal screening, further examinations of each scenario's associated 
programmatic costs should be evaluated in terms of their impact on 
the Italian Health Sanitary budget and their sustainability.
5  | CONCLUSIONS
Holistic screening strategies for hepatitis C should be imple-
mented, considering the prevalence, the reliability of diagnostic 
assays, the natural history of infection, the benefits and risks of 
therapeutic intervention and the potential benefits to society. 
Universal screening and birth cohort screening scenarios, which 
achieve all targets of the HCV elimination goals, were found to be 
cost-effective when compared to the status quo scenario in Italy, 
suggesting a coordinated screening program may be beneficial in 
moving Italy towards elimination of HCV. A graduated screening 
strategy has both clinical and economic benefits to the population 
and could sustain Italy's momentum towards achieving the HCV 
elimination goals. Other countries, particularly those which may 
not have the economic or structural means to implement univer-
sal screening but are interested in developing screening strategies 
based on specific HCV epidemiology, could consider a birth co-
hort approach based on specific epidemiological data and real-life 
treatment rates.
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